首页 > 最新文献

Recent Advances in Inflammation & Allergy Drug Discovery最新文献

英文 中文
An Assessment of BHLHE40 Transcription Factor Level and its Target Cytokines in Patients with Rheumatoid Arthritis. 类风湿关节炎患者BHLHE40转录因子及其靶细胞因子水平的研究
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-02-04 DOI: 10.2174/0127722708331558250129152044
Somayeh Ghotloo, Batol Zamani, Amir-Reza Osatadian, Zeynab Marzhoseyni

Background: Basic helix-loop-helix protein 40 (BHLHE40) can function as both a transcriptional activator and repressor. Recent studies have reported its regulatory functions in T helper (Th)1 and Th17 immune responses. Rheumatoid arthritis (RA) is an autoimmune inflammatory disease in which joints are involved. Both Th1 and Th17 contribute to the pathogenesis of the disease. In the present study, the levels of BHLHE40, interleukin 17 (IL-17), and interferon-gamma (IFN-γ) were assessed in the RA patients.

Methods: Two groups, including RA patients and healthy individuals, were included in the study. The relative expression levels of BHLHE40, IL-17, and IFN-γ were quantified in peripheral blood mononuclear cells (PBMCs) using real-time PCR.

Results: The results showed that the level of BHLHE40 was significantly higher in RA patients compared to the healthy control (P < 0.001) (11.1-fold increase). Accordingly, a significant increase in the levels of IL-17 (8.1 folds increase) (P < 0.021) and IFN-γ (12.7 folds) (P < 0.001) was observed.

Conclusion: Evaluation of the expression level of BHLHE40 in RA patients showed a significant increase. In line with the elevated level of BHLHE40, a significant increase in the expression level of IL-17 and IFN-γ was also detected. These findings point to the possible role of BHLHE40 in the disease course or severity by elevating the levels of inflammatory cytokines, including IL-17 and IFN-γ. Therefore, BHLHE40 might be considered either as a putative biomarker or as a candidate for therapy in a variety of human diseases.

背景:碱性螺旋-环-螺旋蛋白40 (BHLHE40)可作为转录激活因子和抑制因子。最近的研究报道了其在辅助性T (Th)1和Th17免疫应答中的调节作用。类风湿性关节炎(RA)是一种涉及关节的自身免疫性炎症性疾病。Th1和Th17都参与了该疾病的发病机制。本研究评估了RA患者BHLHE40、白细胞介素17 (IL-17)和干扰素γ (IFN-γ)的水平。方法:将RA患者和健康人分为两组进行研究。采用实时荧光定量PCR技术定量外周血单个核细胞(PBMCs)中BHLHE40、IL-17和IFN-γ的相对表达水平。结果:RA患者BHLHE40水平明显高于健康对照组(P < 0.001)(升高11.1倍)。因此,IL-17和IFN-γ水平均显著升高(P < 0.021)和12.7倍(P < 0.001)。结论:评价BHLHE40在RA患者中的表达水平明显升高。与BHLHE40水平升高一致,IL-17和IFN-γ的表达水平也显著升高。这些发现表明BHLHE40可能通过提高炎症细胞因子(包括IL-17和IFN-γ)的水平,在疾病进程或严重程度中发挥作用。因此,BHLHE40可能被认为是一种假定的生物标志物或作为多种人类疾病治疗的候选物。
{"title":"An Assessment of BHLHE40 Transcription Factor Level and its Target Cytokines in Patients with Rheumatoid Arthritis.","authors":"Somayeh Ghotloo, Batol Zamani, Amir-Reza Osatadian, Zeynab Marzhoseyni","doi":"10.2174/0127722708331558250129152044","DOIUrl":"https://doi.org/10.2174/0127722708331558250129152044","url":null,"abstract":"<p><strong>Background: </strong>Basic helix-loop-helix protein 40 (BHLHE40) can function as both a transcriptional activator and repressor. Recent studies have reported its regulatory functions in T helper (Th)1 and Th17 immune responses. Rheumatoid arthritis (RA) is an autoimmune inflammatory disease in which joints are involved. Both Th1 and Th17 contribute to the pathogenesis of the disease. In the present study, the levels of BHLHE40, interleukin 17 (IL-17), and interferon-gamma (IFN-γ) were assessed in the RA patients.</p><p><strong>Methods: </strong>Two groups, including RA patients and healthy individuals, were included in the study. The relative expression levels of BHLHE40, <i>IL</i>-17, and <i>IFN</i>-γ were quantified in peripheral blood mononuclear cells (PBMCs) using real-time PCR.</p><p><strong>Results: </strong>The results showed that the level of <i>BHLHE40</i> was significantly higher in RA patients compared to the healthy control (P < 0.001) (11.1-fold increase). Accordingly, a significant increase in the levels of <i>IL</i>-17 (8.1 folds increase) (P < 0.021) and <i>IFN</i>-γ (12.7 folds) (P < 0.001) was observed.</p><p><strong>Conclusion: </strong>Evaluation of the expression level of <i>BHLHE40</i> in RA patients showed a significant increase. In line with the elevated level of BHLHE40, a significant increase in the expression level of <i>IL</i>-17 and <i>IFN</i>-γ was also detected. These findings point to the possible role of BHLHE40 in the disease course or severity by elevating the levels of inflammatory cytokines, including IL-17 and <i>IFN</i>-γ. Therefore, BHLHE40 might be considered either as a putative biomarker or as a candidate for therapy in a variety of human diseases.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Toxoplasma gondii Perforin-like Proteins (PLPs) to Find the Potential Epitopes for Immunization through in silico Approach. 刚地弓形虫穿孔素样蛋白(PLPs)在寻找潜在免疫表位中的应用
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-31 DOI: 10.2174/0127722708342006250116162454
Seyyed Amir Hosseini, Mohamad Hosein Safari, Davood Siamian, Hamidreza Majidiani, Gholam Basati, Ali Asghari

Background: Toxoplasma gondii (T. gondii) is a widespread apicomplexan parasite that affects approximately one-third of the global population, posing particular risks to pregnant women and individuals with weakened immune systems. Despite its significant impact, there is currently no vaccine available for humans.

Objective: This study employs computational methods (in silico) to investigate the physicochemical, antigenic, and structural properties of Perforin-like proteins (PLPs) from T. gondii, as well as to identify immunogenic epitopes within these antigens.

Methods: For this aim, amino acid sequences of TgPLP1 and TgPLP2 were retrieved and submitted to the ProtParam (physicochemical), VaxiJen v2.0 (antigenicity), NetSurfP-6.0 (2D structure), Robetta (3D structure) web servers, along with the IEDB server to decipher the immunogenic epitopes. Subcellular characteristics such as signal peptide, transmembrane domain, post-translational modifications (PTMs), and cellular localization were also predicted.

Results: Both proteins had a high MW of 125.50 and 92.21, respectively, with an alkaline pI, a 30 hours half-life in mammalian reticulocytes, good thermotolerance (high aliphatic index), and hydrophilicity properties (negative GRAVY). They also showed good antigenicity (0.7021 [PLP1] vs 0.5701 [PLP2]), while they were non-allergenic. Both proteins were extracellular with numerous post-translational modification sites (phosphorylation, glycosylation, and acetylation), and a transmembrane domain was only present in TgPLP1, with no signal peptide in both. Furthermore, numerous immunogenic B- and T-cell epitopes were identified within the TgPLPs sequences, suggesting their potential for inclusion in multi-epitope vaccine designs.

Conclusion: Further studies are needed to confirm these findings and assess the efficacy of the proposed vaccine constructs.

背景:刚地弓形虫(弓形虫)是一种广泛存在的顶复合体寄生虫,影响全球约三分之一的人口,对孕妇和免疫系统较弱的个体构成特别危险。尽管其影响重大,但目前还没有人类可用的疫苗。目的:本研究采用计算机方法研究弓形虫穿孔素样蛋白(Perforin-like protein, PLPs)的理化、抗原性和结构特性,并鉴定这些抗原中的免疫原性表位。方法:为此,检索TgPLP1和TgPLP2的氨基酸序列,并将其提交到ProtParam(物理化学)、VaxiJen v2.0(抗原性)、NetSurfP-6.0 (2D结构)、Robetta (3D结构)web服务器和IEDB服务器上进行免疫原性表位的解码。亚细胞特征,如信号肽、跨膜结构域、翻译后修饰(PTMs)和细胞定位也进行了预测。结果:两种蛋白的分子量分别为125.50和92.21,具有碱性pI,在哺乳动物网织细胞中的半衰期为30小时,具有良好的耐热性(高脂肪指数)和亲水性(负卤)。它们也表现出良好的抗原性(0.7021 [PLP1] vs 0.5701 [PLP2]),同时无致敏性。这两种蛋白都是胞外蛋白,具有大量的翻译后修饰位点(磷酸化、糖基化和乙酰化),而且TgPLP1只存在一个跨膜结构域,两者都没有信号肽。此外,在TgPLPs序列中发现了许多免疫原性B细胞和t细胞表位,这表明它们可能包含在多表位疫苗设计中。结论:需要进一步的研究来证实这些发现并评估所提出的疫苗结构的有效性。
{"title":"Evaluation of Toxoplasma gondii Perforin-like Proteins (PLPs) to Find the Potential Epitopes for Immunization through in silico Approach.","authors":"Seyyed Amir Hosseini, Mohamad Hosein Safari, Davood Siamian, Hamidreza Majidiani, Gholam Basati, Ali Asghari","doi":"10.2174/0127722708342006250116162454","DOIUrl":"https://doi.org/10.2174/0127722708342006250116162454","url":null,"abstract":"<p><strong>Background: </strong>Toxoplasma gondii (T. gondii) is a widespread apicomplexan parasite that affects approximately one-third of the global population, posing particular risks to pregnant women and individuals with weakened immune systems. Despite its significant impact, there is currently no vaccine available for humans.</p><p><strong>Objective: </strong>This study employs computational methods (in silico) to investigate the physicochemical, antigenic, and structural properties of Perforin-like proteins (PLPs) from T. gondii, as well as to identify immunogenic epitopes within these antigens.</p><p><strong>Methods: </strong>For this aim, amino acid sequences of TgPLP1 and TgPLP2 were retrieved and submitted to the ProtParam (physicochemical), VaxiJen v2.0 (antigenicity), NetSurfP-6.0 (2D structure), Robetta (3D structure) web servers, along with the IEDB server to decipher the immunogenic epitopes. Subcellular characteristics such as signal peptide, transmembrane domain, post-translational modifications (PTMs), and cellular localization were also predicted.</p><p><strong>Results: </strong>Both proteins had a high MW of 125.50 and 92.21, respectively, with an alkaline pI, a 30 hours half-life in mammalian reticulocytes, good thermotolerance (high aliphatic index), and hydrophilicity properties (negative GRAVY). They also showed good antigenicity (0.7021 [PLP1] vs 0.5701 [PLP2]), while they were non-allergenic. Both proteins were extracellular with numerous post-translational modification sites (phosphorylation, glycosylation, and acetylation), and a transmembrane domain was only present in TgPLP1, with no signal peptide in both. Furthermore, numerous immunogenic B- and T-cell epitopes were identified within the TgPLPs sequences, suggesting their potential for inclusion in multi-epitope vaccine designs.</p><p><strong>Conclusion: </strong>Further studies are needed to confirm these findings and assess the efficacy of the proposed vaccine constructs.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interleukin-24: A Versatile Regulator of Wound Healing. 白细胞介素-24:伤口愈合的多功能调节剂。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-30 DOI: 10.2174/0127722708349928250108191556
Anju, Uma, Ritu, Mohit Mangla

The skin, as the body's largest organ, is crucial for maintaining homeostasis and providing protection, making it susceptible to wounds from various causes. Wound healing is a complex process involving numerous cellular activities. Any interruptions can lead to chronic, non-healing wounds, which present significant challenges in healthcare. Interleukin-24 (IL-24), a cytokine within the IL-10 family, has become recognized for its significant role in wound healing due to its diverse effects on cellular processes. IL-24 can inhibit keratinocyte migration, potentially leading to chronic wounds, and promote endothelial cell migration and angiogenesis, which are vital for tissue repair. This dual role highlights IL-24's intricate involvement in wound healing, as it can hinder and aid different aspects of the process. Research indicates that IL-24 expression increases in response to inflammatory mediators and is involved in various immune responses, emphasizing its regulatory function. Further research on IL-24's mechanisms and interactions is essential for developing new therapeutic strategies to enhance tissue regeneration and treat chronic wounds and skin disorders. A deeper understanding of IL-24's functions could transform wound care, providing new approaches for effectively managing and treating conditions involving impaired healing.

皮肤作为人体最大的器官,对维持体内平衡和提供保护至关重要,使其容易受到各种原因的伤害。伤口愈合是一个复杂的过程,涉及许多细胞活动。任何中断都可能导致慢性、无法愈合的伤口,这给医疗保健带来了重大挑战。白细胞介素-24 (IL-24)是IL-10家族中的一种细胞因子,由于其对细胞过程的多种影响,在伤口愈合中起着重要作用。IL-24可以抑制角质形成细胞的迁移,可能导致慢性伤口,并促进内皮细胞的迁移和血管生成,这对组织修复至关重要。这种双重作用突出了IL-24在伤口愈合中的复杂参与,因为它可以阻碍和帮助这个过程的不同方面。研究表明,IL-24在炎症介质作用下表达增加,参与多种免疫反应,强调其调节功能。进一步研究IL-24的机制和相互作用对于开发新的治疗策略以促进组织再生和治疗慢性伤口和皮肤疾病至关重要。对IL-24功能的深入了解可以改变伤口护理,为有效管理和治疗涉及愈合受损的疾病提供新的方法。
{"title":"Interleukin-24: A Versatile Regulator of Wound Healing.","authors":"Anju, Uma, Ritu, Mohit Mangla","doi":"10.2174/0127722708349928250108191556","DOIUrl":"https://doi.org/10.2174/0127722708349928250108191556","url":null,"abstract":"<p><p>The skin, as the body's largest organ, is crucial for maintaining homeostasis and providing protection, making it susceptible to wounds from various causes. Wound healing is a complex process involving numerous cellular activities. Any interruptions can lead to chronic, non-healing wounds, which present significant challenges in healthcare. Interleukin-24 (IL-24), a cytokine within the IL-10 family, has become recognized for its significant role in wound healing due to its diverse effects on cellular processes. IL-24 can inhibit keratinocyte migration, potentially leading to chronic wounds, and promote endothelial cell migration and angiogenesis, which are vital for tissue repair. This dual role highlights IL-24's intricate involvement in wound healing, as it can hinder and aid different aspects of the process. Research indicates that IL-24 expression increases in response to inflammatory mediators and is involved in various immune responses, emphasizing its regulatory function. Further research on IL-24's mechanisms and interactions is essential for developing new therapeutic strategies to enhance tissue regeneration and treat chronic wounds and skin disorders. A deeper understanding of IL-24's functions could transform wound care, providing new approaches for effectively managing and treating conditions involving impaired healing.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevention of Chemotherapy-related Oral Mucositis by Topical Timolol: A Prospective Randomized, Double-blind, Placebo-controlled Clinical Trial in Cancer Patients. 局部替马洛尔预防化疗相关口腔黏膜炎:一项前瞻性随机、双盲、安慰剂对照的癌症患者临床试验。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-24 DOI: 10.2174/0127722708312485250115052258
Fatemeh Saghafi, Fatemeh Shaker-Ardakani, Mohsen Nabi-Meybodi, Hassan-Ali Vahedian-Ardakani, Adeleh Sahebnasagh

Background: Timolol is a beta-adrenergic blocker that has been shown to be effective in the healing of wounds. Oral mucositis (OM), an acute inflammation of the oral mucosa, is a bothersome side effect of some regimens of chemotherapy in which the oral mucosa becomes ulcerated. The current study aimed to evaluate the prophylactic effects of timolol mouthwash in preventing OM in adult patients receiving chemotherapy compared to the placebo.

Method: This randomized, double-blind trial was conducted on 30 adult patients receiving chemotherapy regimen, including doxorubicin or 5-fluorouracil (5-FU). The patients were randomized in a 1:1 ratio to receive either timolol 0.5% (w/v) (n = 15) or placebo (n = 15) mouthwash 5 ml three times per day. The outcomes of the study were the intensity of OM evaluated by the World Health Organization (WHO) mucositis scale and OM-related pain based on the Visual Analog Scale (VAS) weekly during the seven weeks of the study period.

Results: The results of the study showed that the scores of WHO mucositis scale significantly decreased in the timolol group compared to the control group during the study [week 1: mean (SD), 0.02 (0.41) in the timolol group, and 0.67 (0.48) in the control group; week 7: mean (SD), 0.33 (0.61) in the timolol group, and 0.87 (0.74) in the control group; P-value = 0.049]. Moreover, the mean pain scores significantly decreased in the first, second, and third weeks in the timolol group compared to the control group (P-value < 0.05).

Conclusion: The results of this preliminary clinical trial demonstrated that among the patients receiving doxorubicin or 5-FU chemotherapy regimens, the preventive use of timolol mouthwash significantly diminished the severity of OM compared to the control group during the seven weeks of follow-up. The severity of pain was also significantly lower during the first three weeks of the study; however, the effect size was less than the minimal clinically important difference. Further studies are required to assess both the long-term efficacy and safety of timolol mouthwash in preventing OM.

背景:替马洛尔是一种β -肾上腺素能阻滞剂,已被证明对伤口愈合有效。口腔黏膜炎(OM)是口腔黏膜的一种急性炎症,是一些化疗方案引起口腔黏膜溃疡的令人烦恼的副作用。目前的研究旨在评估噻洛尔漱口水对接受化疗的成年患者的OM预防作用,并与安慰剂进行比较。方法:对30例接受阿霉素或5-氟尿嘧啶(5-FU)化疗方案的成人患者进行随机、双盲试验。患者按1:1的比例随机分配,接受0.5%替莫洛尔(w/v) (n = 15)或安慰剂(n = 15)漱口水,每次5毫升,每天3次。研究的结果是在研究期间的7周内,每周根据世界卫生组织(WHO)粘膜炎量表评估OM的强度和基于视觉模拟量表(VAS)评估OM相关疼痛。结果:研究结果显示,与对照组相比,替洛尔组在研究第1周期间WHO粘膜炎评分显著降低[周均值(SD),替洛尔组为0.02(0.41),对照组为0.67 (0.48);第7周:平均(SD),替莫洛尔组0.33(0.61),对照组0.87 (0.74);p值= 0.049]。替洛尔组患者第1、2、3周的平均疼痛评分较对照组明显降低(p值< 0.05)。结论:本初步临床试验结果表明,在接受阿霉素或5-FU化疗方案的患者中,在7周的随访期间,预防性使用噻洛尔漱口水与对照组相比,明显减轻了OM的严重程度。在研究的前三周,疼痛的严重程度也明显降低;然而,效应量小于最小临床重要差异。需要进一步的研究来评估噻莫洛尔漱口水预防OM的长期疗效和安全性。
{"title":"Prevention of Chemotherapy-related Oral Mucositis by Topical Timolol: A Prospective Randomized, Double-blind, Placebo-controlled Clinical Trial in Cancer Patients.","authors":"Fatemeh Saghafi, Fatemeh Shaker-Ardakani, Mohsen Nabi-Meybodi, Hassan-Ali Vahedian-Ardakani, Adeleh Sahebnasagh","doi":"10.2174/0127722708312485250115052258","DOIUrl":"https://doi.org/10.2174/0127722708312485250115052258","url":null,"abstract":"<p><strong>Background: </strong>Timolol is a beta-adrenergic blocker that has been shown to be effective in the healing of wounds. Oral mucositis (OM), an acute inflammation of the oral mucosa, is a bothersome side effect of some regimens of chemotherapy in which the oral mucosa becomes ulcerated. The current study aimed to evaluate the prophylactic effects of timolol mouthwash in preventing OM in adult patients receiving chemotherapy compared to the placebo.</p><p><strong>Method: </strong>This randomized, double-blind trial was conducted on 30 adult patients receiving chemotherapy regimen, including doxorubicin or 5-fluorouracil (5-FU). The patients were randomized in a 1:1 ratio to receive either timolol 0.5% (w/v) (n = 15) or placebo (n = 15) mouthwash 5 ml three times per day. The outcomes of the study were the intensity of OM evaluated by the World Health Organization (WHO) mucositis scale and OM-related pain based on the Visual Analog Scale (VAS) weekly during the seven weeks of the study period.</p><p><strong>Results: </strong>The results of the study showed that the scores of WHO mucositis scale significantly decreased in the timolol group compared to the control group during the study [week 1: mean (SD), 0.02 (0.41) in the timolol group, and 0.67 (0.48) in the control group; week 7: mean (SD), 0.33 (0.61) in the timolol group, and 0.87 (0.74) in the control group; P-value = 0.049]. Moreover, the mean pain scores significantly decreased in the first, second, and third weeks in the timolol group compared to the control group (P-value < 0.05).</p><p><strong>Conclusion: </strong>The results of this preliminary clinical trial demonstrated that among the patients receiving doxorubicin or 5-FU chemotherapy regimens, the preventive use of timolol mouthwash significantly diminished the severity of OM compared to the control group during the seven weeks of follow-up. The severity of pain was also significantly lower during the first three weeks of the study; however, the effect size was less than the minimal clinically important difference. Further studies are required to assess both the long-term efficacy and safety of timolol mouthwash in preventing OM.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hibiscus Sabdariffa Linn: Phytochemical Impact on the Mechanism of Neuroprotective and Anti-inflammatory Pathways. 芙蓉:植物化学对神经保护和抗炎通路机制的影响。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.2174/0127722708302750240916064255
Renuka Ekka, Bharti Ahirwar

The Hibiscus sabdariffa plant is an herbaceous member of the Malvaceae family. It is a widely recognized herb with medicinal properties. It is utilized extensively in many traditional medical practices along with delicious food items, like jams, puddings, and cakes. The purpose of this review was to investigate and compile all of the available data and evidence about the calyxes of Hibiscus sabdariffa with a particular focus on their nutritional composition, bioactive components, and therapeutic benefits. This article provides a comprehensive overview of the plant's traditional usage, pharmacognostic characterization, nutritional and phytochemical composition, and pharmacological properties. This paper elucidates the mechanisms by which Hibiscus sabdariffa exerts neuroprotective and anti-inflammatory effects in managing neurological disorders. Additionally, Hibiscus sabdariffa has been shown to prevent memory impairment, which may be attributed to its effects on neuroinflammation and amyloidogenesis. Hibiscus sabdariffa has been reported to have anti-inflammatory effects due to the presence of polyphenol compounds that possess anti- inflammatory properties. Flavonoids are also commonly found in it, which inhibit the transcription factor nuclear factor kappa B. This plant has a variety of health benefits, including antioxidant, antidepressant, diuretic, antihyperlipidemic, anti-obesity, hepatoprotective, anti-inflammatory, anti-cancer, antimicrobial, and neuroprotective activities. Based on the literature, this review provides a thorough analysis of the pharmacological and phytochemical characteristics of Hibiscus sabdariffa.

芙蓉是锦葵科的一种草本植物。它是一种被广泛认可的具有药用特性的草药。它被广泛应用于许多传统医学实践,以及美味的食物,如果酱、布丁和蛋糕。本综述的目的是调查和整理所有关于芙蓉花萼的现有数据和证据,特别关注其营养成分、生物活性成分和治疗效果。本文全面介绍了该植物的传统用途、生药学特性、营养成分和植物化学成分以及药理特性。本文阐述了芙蓉在治疗神经系统疾病中发挥神经保护和抗炎作用的机制。此外,木槿已被证明可以预防记忆障碍,这可能归因于其对神经炎症和淀粉样蛋白形成的影响。据报道,木槿具有抗炎作用,因为它含有具有抗炎特性的多酚化合物。黄酮类化合物也常见于其中,它抑制转录因子核因子κ b。这种植物具有多种健康益处,包括抗氧化、抗抑郁、利尿、降血脂、抗肥胖、保肝、抗炎、抗癌、抗菌和神经保护活性。本文在文献综述的基础上,对芙蓉的药理和植物化学特性进行了较为全面的分析。
{"title":"<i>Hibiscus Sabdariffa</i> Linn: Phytochemical Impact on the Mechanism of Neuroprotective and Anti-inflammatory Pathways.","authors":"Renuka Ekka, Bharti Ahirwar","doi":"10.2174/0127722708302750240916064255","DOIUrl":"https://doi.org/10.2174/0127722708302750240916064255","url":null,"abstract":"<p><p>The <i>Hibiscus sabdariffa</i> plant is an herbaceous member of the Malvaceae family. It is a widely recognized herb with medicinal properties. It is utilized extensively in many traditional medical practices along with delicious food items, like jams, puddings, and cakes. The purpose of this review was to investigate and compile all of the available data and evidence about the calyxes of <i>Hibiscus sabdariffa</i> with a particular focus on their nutritional composition, bioactive components, and therapeutic benefits. This article provides a comprehensive overview of the plant's traditional usage, pharmacognostic characterization, nutritional and phytochemical composition, and pharmacological properties. This paper elucidates the mechanisms by which <i>Hibiscus sabdariffa</i> exerts neuroprotective and anti-inflammatory effects in managing neurological disorders. Additionally, <i>Hibiscus sabdariffa</i> has been shown to prevent memory impairment, which may be attributed to its effects on neuroinflammation and amyloidogenesis. <i>Hibiscus sabdariffa</i> has been reported to have anti-inflammatory effects due to the presence of polyphenol compounds that possess anti- inflammatory properties. Flavonoids are also commonly found in it, which inhibit the transcription factor nuclear factor kappa B. This plant has a variety of health benefits, including antioxidant, antidepressant, diuretic, antihyperlipidemic, anti-obesity, hepatoprotective, anti-inflammatory, anti-cancer, antimicrobial, and neuroprotective activities. Based on the literature, this review provides a thorough analysis of the pharmacological and phytochemical characteristics of Hibiscus sabdariffa.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"19 2","pages":"173-188"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking Toll-Like Receptors: Targeting Therapeutics for Respiratory Tract Infections and Inflammatory Disorders. 解锁toll样受体:呼吸道感染和炎症性疾病的靶向治疗。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.2174/0127722708329138240926073013
Vishal Pandey, Debasis Sen, Sunny Rathee, Sakshi Soni, Shashank Mishra, Sanjay K Jain, Umesh K Patil

The Toll-like Receptors (TLRs) family has significantly enhanced the understanding of innate immune responses by identifying and responding to various microbes or host-derived organisms. TLRs contribute to these responses by increasing the levels of cytokines, interleukins, and other inflammatory mediators through multiple pathways. Located both intracellularly and on the surface of various cells and tissues, including vascular smooth muscles (VSMs) and myocardium cells, TLRs play distinct roles in innate immune activation, such as recognizing pathogen-associated molecular patterns (PAMPs) and activating downstream signaling pathways. In the context of COVID-19, TLRs are critically involved in the pathophysiology by mediating excessive inflammatory responses that exacerbate disease severity, influencing both the acute phase and long-term outcomes. It has been observed that inflammatory diseases such as atherosclerosis, viral myocarditis, and other comorbidities associated with the spread of COVID-19 have increased, although the exact mechanisms remain not fully understood. Nonetheless, there is evidence of TLR-mediated increased pro-inflammatory signaling by different mechanisms in these diseases. This review explains the role of TLRs in various inflammatory diseases related to COVID-19, including viral myocarditis, acute lung infections, and atherosclerosis. Furthermore, the review discusses various herbal drugs, such as Platycodon grandiflorum, Acanthopanax senticosus, Scutellaria baicalensis Georgi, and Engelhardia roxburghiana, and their mechanisms of action on TLRs, including NF-κB, MyD88-dependent, MyD88-independent pathways, and Plasmacytoid DCs. Enhanced clarity on TLRs' specific contributions to COVID-19 pathophysiology and stronger evidence supporting herbal interventions targeting TLRs could improve the impact and applicability of these findings in clinical settings.

toll样受体(TLRs)家族通过识别和响应各种微生物或宿主来源的生物,显著增强了对先天免疫反应的理解。tlr通过多种途径增加细胞因子、白细胞介素和其他炎症介质的水平,从而促进这些反应。tlr位于细胞内和各种细胞和组织的表面,包括血管平滑肌(VSMs)和心肌细胞,在先天免疫激活中发挥着独特的作用,例如识别病原体相关分子模式(pathogen-associated molecular patterns, PAMPs)和激活下游信号通路。在COVID-19的背景下,tlr通过介导过度炎症反应,加剧疾病严重程度,影响急性期和长期结局,在病理生理学中发挥关键作用。据观察,与COVID-19传播相关的炎症性疾病,如动脉粥样硬化、病毒性心肌炎和其他合并症有所增加,尽管其确切机制尚不完全清楚。尽管如此,有证据表明,在这些疾病中,tlr介导的促炎信号通过不同的机制增加。本文综述了TLRs在与COVID-19相关的各种炎症性疾病中的作用,包括病毒性心肌炎、急性肺部感染和动脉粥样硬化。综述了桔梗、刺五加、黄芩、刺五加等中草药对tlr的作用机制,包括NF-κB、myd88依赖性通路、myd88非依赖性通路和浆细胞样dc的作用机制。进一步明确tlr对COVID-19病理生理的具体贡献,并有更有力的证据支持针对tlr的草药干预,可以提高这些发现在临床环境中的影响和适用性。
{"title":"Unlocking Toll-Like Receptors: Targeting Therapeutics for Respiratory Tract Infections and Inflammatory Disorders.","authors":"Vishal Pandey, Debasis Sen, Sunny Rathee, Sakshi Soni, Shashank Mishra, Sanjay K Jain, Umesh K Patil","doi":"10.2174/0127722708329138240926073013","DOIUrl":"https://doi.org/10.2174/0127722708329138240926073013","url":null,"abstract":"<p><p>The Toll-like Receptors (TLRs) family has significantly enhanced the understanding of innate immune responses by identifying and responding to various microbes or host-derived organisms. TLRs contribute to these responses by increasing the levels of cytokines, interleukins, and other inflammatory mediators through multiple pathways. Located both intracellularly and on the surface of various cells and tissues, including vascular smooth muscles (VSMs) and myocardium cells, TLRs play distinct roles in innate immune activation, such as recognizing pathogen-associated molecular patterns (PAMPs) and activating downstream signaling pathways. In the context of COVID-19, TLRs are critically involved in the pathophysiology by mediating excessive inflammatory responses that exacerbate disease severity, influencing both the acute phase and long-term outcomes. It has been observed that inflammatory diseases such as atherosclerosis, viral myocarditis, and other comorbidities associated with the spread of COVID-19 have increased, although the exact mechanisms remain not fully understood. Nonetheless, there is evidence of TLR-mediated increased pro-inflammatory signaling by different mechanisms in these diseases. This review explains the role of TLRs in various inflammatory diseases related to COVID-19, including viral myocarditis, acute lung infections, and atherosclerosis. Furthermore, the review discusses various herbal drugs, such as <i>Platycodon grandiflorum, Acanthopanax senticosus, Scutellaria baicalensis Georgi</i>, and <i>Engelhardia roxburghiana</i>, and their mechanisms of action on TLRs, including NF-κB, MyD88-dependent, MyD88-independent pathways, and Plasmacytoid DCs. Enhanced clarity on TLRs' specific contributions to COVID-19 pathophysiology and stronger evidence supporting herbal interventions targeting TLRs could improve the impact and applicability of these findings in clinical settings.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"19 3","pages":"303-315"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Potential Anti-psoriatic Effects of Andrographolide: A Comparative Study to Topical Corticosteroids. 穿心莲内酯潜在的抗银屑病作用:与外用皮质类固醇的比较研究
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.2174/0127722708296983240424102212
Indira Dharmasamitha, Luh Made Mas Rusyati, Dyah Kanya Wati, I Made Agus Gelgel Wirasuta

Background: Andrographolide (AP), a bioactive anti-inflammatory compound of Sambiloto, inhibits NF-κB, TNF-α, and interleukin IL-6. Nowadays, molecular docking simulation between AP and dexamethasone against NF-κB receptor presented the energy AP higher than dexamethasone. This becomes a potential treatment for psoriasis.

Objective: This manuscript reported the effectiveness of AP from Sambiloto in treating psoriasis compared to topical steroids.

Methods: This study conducted TLC analysis of AP content and its metabolite impurities, emulgel formulation, molecular docking, in-silico skin toxicity study, and in-vivo anti-psoriatic activity. This was a combination study of an in-silico study and an in-vivo study. This in-silico study was analyzed through multivariate statistical analysis (PCA) to elucidate the data constellation relationship of andrographolide derivatives with several target proteins. The intervention was performed in seven days. The PASI score, molecular parameters (IL-6, IL-17, VEGF, and TNF-a levels), and histopathological findings were assessed.

Results: Molecular docking results revealed andrographolide to exhibit a relatively high binding affinity towards IL-6, NF-kB, and TNF-α which is comparable to the corticosteroids, andrographolide also shares similar residue interaction profile with each of the respective protein's native ligand. In the in-vivo study, we found several parameters statistically significantly different regarding the intervention, including final PASI score (p = 0.017), redness (p = 0.017), scale (p = 0.040), thickness (p = 0.023), total histopathology of psoriasis score (p = 0.037), keratin layer score (p = 0.018).

Conclusion: Emulgel AP 0.1% could lower the anti-inflammatory agent, which is vital to psoriasis progression.

背景:穿心莲内酯(Andrographolide,AP)是一种生物活性抗炎化合物,可抑制 NF-κB、TNF-α 和白细胞介素 IL-6。目前,AP 与地塞米松针对 NF-κB 受体的分子对接模拟显示,AP 的能量高于地塞米松。这成为治疗银屑病的一种潜在方法:本手稿报告了桑比洛托 AP 与外用类固醇相比在治疗银屑病方面的有效性:本研究对 AP 的含量及其代谢物杂质、凝胶配方、分子对接、体内皮肤毒性研究和体内抗银屑病活性进行了 TLC 分析。这是一项综合了室内研究和体内研究的研究。通过多变量统计分析(PCA)对这项体内研究进行了分析,以阐明穿心莲内酯衍生物与几种靶蛋白之间的数据星座关系。干预为期七天。对PASI评分、分子参数(IL-6、IL-17、VEGF和TNF-a水平)以及组织病理学结果进行了评估:分子对接结果显示,穿心莲内酯与IL-6、NF-kB和TNF-α的结合亲和力较高,与皮质类固醇的结合亲和力相当。在体内研究中,我们发现有几个参数在统计学上与干预有显著差异,包括最终的 PASI 评分(p = 0.017)、发红(p = 0.017)、鳞屑(p = 0.040)、厚度(p = 0.023)、银屑病组织病理学总评分(p = 0.037)、角质层评分(p = 0.018):结论:Emulgel AP 0.1%可降低抗炎剂,而抗炎剂对银屑病的发展至关重要。
{"title":"The Potential Anti-psoriatic Effects of Andrographolide: A Comparative Study to Topical Corticosteroids.","authors":"Indira Dharmasamitha, Luh Made Mas Rusyati, Dyah Kanya Wati, I Made Agus Gelgel Wirasuta","doi":"10.2174/0127722708296983240424102212","DOIUrl":"10.2174/0127722708296983240424102212","url":null,"abstract":"<p><strong>Background: </strong>Andrographolide (AP), a bioactive anti-inflammatory compound of Sambiloto, inhibits NF-κB, TNF-α, and interleukin IL-6. Nowadays, molecular docking simulation between AP and dexamethasone against NF-κB receptor presented the energy AP higher than dexamethasone. This becomes a potential treatment for psoriasis.</p><p><strong>Objective: </strong>This manuscript reported the effectiveness of AP from Sambiloto in treating psoriasis compared to topical steroids.</p><p><strong>Methods: </strong>This study conducted TLC analysis of AP content and its metabolite impurities, emulgel formulation, molecular docking, <i>in-silico</i> skin toxicity study, and <i>in-vivo</i> anti-psoriatic activity. This was a combination study of an <i>in-silico</i> study and an <i>in-vivo</i> study. This <i>in-silico</i> study was analyzed through multivariate statistical analysis (PCA) to elucidate the data constellation relationship of andrographolide derivatives with several target proteins. The intervention was performed in seven days. The PASI score, molecular parameters (IL-6, IL-17, VEGF, and TNF-a levels), and histopathological findings were assessed.</p><p><strong>Results: </strong>Molecular docking results revealed andrographolide to exhibit a relatively high binding affinity towards IL-6, NF-kB, and TNF-α which is comparable to the corticosteroids, andrographolide also shares similar residue interaction profile with each of the respective protein's native ligand. In the <i>in-vivo</i> study, we found several parameters statistically significantly different regarding the intervention, including final PASI score (p = 0.017), redness (p = 0.017), scale (p = 0.040), thickness (p = 0.023), total histopathology of psoriasis score (p = 0.037), keratin layer score (p = 0.018).</p><p><strong>Conclusion: </strong>Emulgel AP 0.1% could lower the anti-inflammatory agent, which is vital to psoriasis progression.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"46-70"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monitoring Tacrolimus and Cyclosporine Blood Trough Levels and the Capacity of Anti-oxidant after Kidney Transplantation: A Patent Perspective. 肾移植后监测他克莫司和环孢素血槽水平和抗氧化能力:专利观点。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.2174/0127722708319486241202113259
Zahra Tolou-Ghamari

Background: It is well known that acute or chronic kidney injury could be due to free radicals and pro-oxidants. This investigation aimed to monitor tacrolimus or cyclosporine blood trough levels and anti-oxidant capacity after kidney transplantation.

Methods: There was no intervention in the routine management of transplant recipients. The sample size (n=70) included healthy individuals and kidney-transplanted recipients (n=25 on tacrolimus and n=10 on cyclosporine). The study population was matched for age. The attained information was examined by using the Statistical Package (SPSS Inc, Chicago, IL, USA). The significance level was considered as P ≤ 0.05.

Results: In healthy individuals, the mean ± SD for the capacity of antioxidants was 91.9 ± 16.6 (u/ml), which was significantly higher when compared to the mean value of 28.5 ± 22.6 (u/ml) versus 24.7 ± 25.5 (u/ml), kidney recipients with tacrolimus versus cyclosporine (P ≤ 0.04) as immunosuppressive drugs. The mean value of tacrolimus levels was 14.6 ± 6.4 (ng/ml). The correlation between tacrolimus and cyclosporine trough levels and anti-oxidant capacity was 0.19 (P ≤ 0.14). There were no significant differences regarding age in cases and controls (P ≤ 0.42).

Conclusion: This study showed that the capacity of anti-oxidants in kidney transplant recipients, those on tacrolimus or cyclosporine, might be lower than in healthy individuals. Subsequent investigations are recommended to delve into the therapeutic consequences of the influence of antioxidant therapies on the clinical outcomes of transplanted recipients.

背景:众所周知,急性或慢性肾损伤可由自由基和促氧化剂引起。本研究旨在监测肾移植术后他克莫司或环孢素血槽水平和抗氧化能力。方法:对移植受者的日常管理不进行干预。样本量(n=70)包括健康个体和肾移植受体(他克莫司组25例,环孢素组10例)。研究人群的年龄相匹配。获得的信息使用Statistical Package (SPSS Inc ., Chicago, IL, USA)进行检验。以P≤0.05为显著性水平。结果:在健康人群中,抗氧化剂能力的平均值±SD为91.9±16.6 (u/ml),显著高于他克莫司与环孢素两种免疫抑制剂的平均值28.5±22.6 (u/ml)和24.7±25.5 (u/ml) (P≤0.04)。他克莫司水平平均值为14.6±6.4 (ng/ml)。他克莫司和环孢素谷水平与抗氧化能力的相关性为0.19 (P≤0.14)。病例与对照组年龄差异无统计学意义(P≤0.42)。结论:本研究表明,肾移植受者(服用他克莫司或环孢素)的抗氧化剂能力可能低于健康人。后续研究建议深入研究抗氧化治疗对移植受者临床结果影响的治疗结果。
{"title":"Monitoring Tacrolimus and Cyclosporine Blood Trough Levels and the Capacity of Anti-oxidant after Kidney Transplantation: A Patent Perspective.","authors":"Zahra Tolou-Ghamari","doi":"10.2174/0127722708319486241202113259","DOIUrl":"https://doi.org/10.2174/0127722708319486241202113259","url":null,"abstract":"<p><strong>Background: </strong>It is well known that acute or chronic kidney injury could be due to free radicals and pro-oxidants. This investigation aimed to monitor tacrolimus or cyclosporine blood trough levels and anti-oxidant capacity after kidney transplantation.</p><p><strong>Methods: </strong>There was no intervention in the routine management of transplant recipients. The sample size (n=70) included healthy individuals and kidney-transplanted recipients (n=25 on tacrolimus and n=10 on cyclosporine). The study population was matched for age. The attained information was examined by using the Statistical Package (SPSS Inc, Chicago, IL, USA). The significance level was considered as P ≤ 0.05.</p><p><strong>Results: </strong>In healthy individuals, the mean ± SD for the capacity of antioxidants was 91.9 ± 16.6 (u/ml), which was significantly higher when compared to the mean value of 28.5 ± 22.6 (u/ml) versus 24.7 ± 25.5 (u/ml), kidney recipients with tacrolimus versus cyclosporine (P ≤ 0.04) as immunosuppressive drugs. The mean value of tacrolimus levels was 14.6 ± 6.4 (ng/ml). The correlation between tacrolimus and cyclosporine trough levels and anti-oxidant capacity was 0.19 (P ≤ 0.14). There were no significant differences regarding age in cases and controls (P ≤ 0.42).</p><p><strong>Conclusion: </strong>This study showed that the capacity of anti-oxidants in kidney transplant recipients, those on tacrolimus or cyclosporine, might be lower than in healthy individuals. Subsequent investigations are recommended to delve into the therapeutic consequences of the influence of antioxidant therapies on the clinical outcomes of transplanted recipients.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"19 3","pages":"374-379"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparative Study of Dexamethasone and Methylprednisolone in COVID-19 Patients: Clinical Outcomes and Inflammatory Markers. 地塞米松与甲基强的松龙治疗COVID-19患者的比较研究:临床结局和炎症标志物
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.2174/0127722708310247240718100251
Alireza Ziaei Moghaddam, Mostafa Soleimani, Behnam Imani, Sepideh Hejazi, Mohammadhossein Taherynejad, Mona Kabiri, Maryam Emadzadeh, Sahar Ravanshad

Background: The Coronavirus disease 2019 (COVID-19) pandemic, prompted by SARS-CoV-2, has created complicated health crises. An excessive inflammatory response and cytokine storm characterize severe COVID-19. Corticosteroids like dexamethasone and methylprednisolone are used for their anti-inflammatory effects, but comparisons of their efficacy are lacking.

Objective: This study seeks to rigorously assess and contrast the effectiveness of dexamethasone and methylprednisolone in combating COVID-19 infections.

Methods: This retrospective clinical study evaluates the effects of these two corticosteroids by reviewing the files of 500 hospitalized COVID-19 patients. The baseline characteristics of the patients, chest CT severity score, type of steroid prescription, duration of hospitalization and steroid prescription, dosage of corticosteroid therapy, their recovery status, hospital mortality, and specific disease severity-associated markers, such as lactate dehydrogenase (LDH), complete blood count (CBC), C-reactive protein (CRP), and Erythrocyte sedimentation rate (ESR) were collected and compared.

Results: The study found no significant difference in most disease severity-associated markers between the two corticosteroid groups. However, lower mortality rates and shortened hospital stays were significantly associated with dexamethasone, especially in critical patient groups. A detailed analysis of inflammatory markers suggested minimal differences based on the type of corticosteroid used.

Conclusion: The study indicates that dexamethasone may have some advantages in specific clinical outcomes. Further research needs to explore the mechanisms involved despite similar anti-inflammatory profiles.

背景:由SARS-CoV-2引发的2019冠状病毒病(COVID-19)大流行造成了复杂的健康危机。过度的炎症反应和细胞因子风暴是严重COVID-19的特征。地塞米松和甲基强的松龙等皮质类固醇因其抗炎作用而被使用,但缺乏对其功效的比较。目的:本研究旨在严格评估和对比地塞米松和甲基强的松龙对抗COVID-19感染的有效性。方法:回顾性临床分析500例新冠肺炎住院患者资料,评价两种糖皮质激素的疗效。收集并比较患者的基线特征、胸部CT严重程度评分、类固醇处方类型、住院时间和类固醇处方、皮质类固醇治疗剂量、恢复状况、住院死亡率和特定疾病严重程度相关标志物,如乳酸脱氢酶(LDH)、全血细胞计数(CBC)、c反应蛋白(CRP)和红细胞沉降率(ESR)。结果:研究发现,在大多数疾病严重程度相关的标志物在两个皮质类固醇组之间没有显著差异。然而,较低的死亡率和缩短的住院时间与地塞米松显著相关,特别是在危重患者群体中。对炎症标志物的详细分析表明,根据使用的皮质类固醇的类型,差异很小。结论:本研究提示地塞米松在特定临床结果上可能具有一定优势。尽管具有类似的抗炎特征,但仍需进一步研究其相关机制。
{"title":"A Comparative Study of Dexamethasone and Methylprednisolone in COVID-19 Patients: Clinical Outcomes and Inflammatory Markers.","authors":"Alireza Ziaei Moghaddam, Mostafa Soleimani, Behnam Imani, Sepideh Hejazi, Mohammadhossein Taherynejad, Mona Kabiri, Maryam Emadzadeh, Sahar Ravanshad","doi":"10.2174/0127722708310247240718100251","DOIUrl":"https://doi.org/10.2174/0127722708310247240718100251","url":null,"abstract":"<p><strong>Background: </strong>The Coronavirus disease 2019 (COVID-19) pandemic, prompted by SARS-CoV-2, has created complicated health crises. An excessive inflammatory response and cytokine storm characterize severe COVID-19. Corticosteroids like dexamethasone and methylprednisolone are used for their anti-inflammatory effects, but comparisons of their efficacy are lacking.</p><p><strong>Objective: </strong>This study seeks to rigorously assess and contrast the effectiveness of dexamethasone and methylprednisolone in combating COVID-19 infections.</p><p><strong>Methods: </strong>This retrospective clinical study evaluates the effects of these two corticosteroids by reviewing the files of 500 hospitalized COVID-19 patients. The baseline characteristics of the patients, chest CT severity score, type of steroid prescription, duration of hospitalization and steroid prescription, dosage of corticosteroid therapy, their recovery status, hospital mortality, and specific disease severity-associated markers, such as lactate dehydrogenase (LDH), complete blood count (CBC), C-reactive protein (CRP), and Erythrocyte sedimentation rate (ESR) were collected and compared.</p><p><strong>Results: </strong>The study found no significant difference in most disease severity-associated markers between the two corticosteroid groups. However, lower mortality rates and shortened hospital stays were significantly associated with dexamethasone, especially in critical patient groups. A detailed analysis of inflammatory markers suggested minimal differences based on the type of corticosteroid used.</p><p><strong>Conclusion: </strong>The study indicates that dexamethasone may have some advantages in specific clinical outcomes. Further research needs to explore the mechanisms involved despite similar anti-inflammatory profiles.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"19 2","pages":"259-268"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in Phytochemical-based Nanocarrier Approaches for Rheumatoid Arthritis: Challenges and Scope for Future-generation Formulations. 基于植物化学的类风湿性关节炎纳米载体方法的进展:未来一代制剂的挑战和范围。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.2174/0127722708304673240903184606
Sandhya Mishra, Ravindra Kumar Pandey, Shiv Shankar Shukla, Disha Kesharwani

The study aims to investigate and assess the effectiveness of current novel techniques for the preparation of an efficient nanocarrier system in resolving the drawbacks associated with the delivery of herbal bioactives to treat rheumatoid arthritis. Systematic utilization of various search engines like Science Direct, Pubmed, Shodhganga, Google Scholar, and Google Patent databases based on various sets of key phrases has been performed. All the findings from these data have been studied and briefed based on their relevant and irrelevant information. The current study summarizes the existing research and development of new nano-formulations with a focus on herbal bioactive compounds for treating rheumatoid arthritis. Physicochemical properties of phytoconstituents, such as low aqueous solubility, low permeation coefficient, and chemical instability, poor bioavailability, short plasma half-life, and ultimately sub-therapeutic efficacy, limit their clinical translation despite their great potency. The utilization of Phytochemical-Based Nanocarrier Approaches for rheumatoid arthritis can be a milestone as a major population is affected by this disease worldwide. The intensive study recapitulates that novel drug delivery systems can provide new opportunities to efficiently deliver herbal bioactives with improved pharmacokinetic and pharmacodynamic properties. The exhaustive study concluded that transferosomes, ethosomes, transethosomes, niosomes, phytosomes, Solid Lipid Nanoparticles (SLN), Nano Lipid Carriers (NLC), bilosomes and hylurosomes are some of the efficient nanocarrier systems that may impart numerous benefits to the delivery of herbal bioactives for treatment of RA. These nanocarrier systems fabricated with phytoconstituents flaunt the evident promising benefits of improved aqueous solubility, low first-pass metabolism with upgraded bioavailability, sustained release action, resistance to enzymatic degradation etc., providing support in rheumatoid arthritis recovery. This review discusses that the upgradation of the pharmacological action and other relevant issues of herbal bioactives are possible by utilizing novel drug delivery systems, resulting in successful development of nano-loaded herbal bioactives. It also focuses on highlighting the pioneering progression in the field of herbal bioactives-loaded nanocarrier systems for rheumatoid arthritis both in vitro and in vivo along with their advanced preparation methods and applications and discussing the opportunities for further prospects. This compiled informative review will enlighten various researchers in the field of delivering herbal bioactives for rheumatoid arthritis.

该研究旨在调查和评估当前制备高效纳米载体系统的新技术的有效性,以解决与传递草药生物活性物治疗类风湿性关节炎相关的缺陷。系统利用Science Direct、Pubmed、Shodhganga、谷歌Scholar、谷歌Patent等多种搜索引擎,基于不同的关键短语集。从这些数据中得出的所有结论都是根据相关和不相关的信息进行研究和简要介绍的。本研究综述了目前治疗类风湿性关节炎的新型纳米制剂的研究和开发,重点介绍了治疗类风湿性关节炎的草药生物活性化合物。植物成分的物理化学性质,如低水溶性、低渗透系数、化学不稳定性、生物利用度差、血浆半衰期短以及最终的亚治疗效果,限制了它们的临床转化,尽管它们具有巨大的效力。基于植物化学的纳米载体方法在类风湿关节炎治疗中的应用是一个里程碑,因为世界范围内的主要人群受到这种疾病的影响。这项深入的研究总结了新的药物传递系统可以提供新的机会,有效地传递具有改善药代动力学和药效学特性的草药生物活性。这项详尽的研究得出结论,转移体、脂质体、转脂体、乳质体、磷脂质体、固体脂质纳米颗粒(SLN)、纳米脂质载体(NLC)、胆囊体和羟脲质体是一些有效的纳米载体系统,可以为治疗类风湿性关节炎的草药生物活性物质的输送带来许多好处。这些由植物成分制成的纳米载体系统具有改善水溶性、低首过代谢和提高生物利用度、缓释作用、抗酶降解等明显的有希望的好处,为类风湿关节炎的康复提供支持。本文讨论了利用新型给药系统可以提高草药生物活性物质的药理作用和其他相关问题,从而成功开发纳米负载的草药生物活性物质。它还着重强调了类风湿性关节炎的体外和体内草药生物活性负载纳米载体系统领域的开创性进展,以及它们的先进制备方法和应用,并讨论了进一步前景的机会。这个汇编的信息综述将启发各种研究人员在提供类风湿性关节炎的草药生物活性领域。
{"title":"Advances in Phytochemical-based Nanocarrier Approaches for Rheumatoid Arthritis: Challenges and Scope for Future-generation Formulations.","authors":"Sandhya Mishra, Ravindra Kumar Pandey, Shiv Shankar Shukla, Disha Kesharwani","doi":"10.2174/0127722708304673240903184606","DOIUrl":"https://doi.org/10.2174/0127722708304673240903184606","url":null,"abstract":"<p><p>The study aims to investigate and assess the effectiveness of current novel techniques for the preparation of an efficient nanocarrier system in resolving the drawbacks associated with the delivery of herbal bioactives to treat rheumatoid arthritis. Systematic utilization of various search engines like Science Direct, Pubmed, Shodhganga, Google Scholar, and Google Patent databases based on various sets of key phrases has been performed. All the findings from these data have been studied and briefed based on their relevant and irrelevant information. The current study summarizes the existing research and development of new nano-formulations with a focus on herbal bioactive compounds for treating rheumatoid arthritis. Physicochemical properties of phytoconstituents, such as low aqueous solubility, low permeation coefficient, and chemical instability, poor bioavailability, short plasma half-life, and ultimately sub-therapeutic efficacy, limit their clinical translation despite their great potency. The utilization of Phytochemical-Based Nanocarrier Approaches for rheumatoid arthritis can be a milestone as a major population is affected by this disease worldwide. The intensive study recapitulates that novel drug delivery systems can provide new opportunities to efficiently deliver herbal bioactives with improved pharmacokinetic and pharmacodynamic properties. The exhaustive study concluded that transferosomes, ethosomes, transethosomes, niosomes, phytosomes, Solid Lipid Nanoparticles (SLN), Nano Lipid Carriers (NLC), bilosomes and hylurosomes are some of the efficient nanocarrier systems that may impart numerous benefits to the delivery of herbal bioactives for treatment of RA. These nanocarrier systems fabricated with phytoconstituents flaunt the evident promising benefits of improved aqueous solubility, low first-pass metabolism with upgraded bioavailability, sustained release action, resistance to enzymatic degradation etc., providing support in rheumatoid arthritis recovery. This review discusses that the upgradation of the pharmacological action and other relevant issues of herbal bioactives are possible by utilizing novel drug delivery systems, resulting in successful development of nano-loaded herbal bioactives. It also focuses on highlighting the pioneering progression in the field of herbal bioactives-loaded nanocarrier systems for rheumatoid arthritis both <i>in vitro</i> and <i>in vivo</i> along with their advanced preparation methods and applications and discussing the opportunities for further prospects. This compiled informative review will enlighten various researchers in the field of delivering herbal bioactives for rheumatoid arthritis.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"19 2","pages":"189-212"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Recent Advances in Inflammation & Allergy Drug Discovery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1